TELO
Telomir Pharmaceuticals, Inc. Common Stock
Biotechnology
Market Cap$46M
5Y Perf.-85.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TELO vs ADTX
Revenue, margins, valuation, and 5-year total return — side by side.
ADTX
Aditxt, Inc.
Biotechnology
Market Cap$70K
5Y Perf.-100.0%
TELO vs ADTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TELO | ADTX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $46M | $70K |
| Revenue (TTM) | $0.00 | $6K |
| Net Income (TTM) | $-10M | $-42M |
| Gross Margin | — | -34.1% |
| Operating Margin | — | -3457.1% |
| Total Debt | $0.00 | $7M |
| Cash & Equiv. | $7M | $833K |
TELO vs ADTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TELO
ADTX
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| Telomir Pharmaceuti… (TELO) | 100 | 14.8 | -85.2% |
| Aditxt, Inc. (ADTX) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TELO vs ADTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TELO leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aditxt, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
TELO
Telomir Pharmaceuticals, Inc. Common Stock
The Growth Play
TELO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 41.1%
- -80.9% 10Y total return vs ADTX's -100.0%
- 102.8% revenue growth vs ADTX's -79.2%
Best for: growth exposure and long-term compounding
ADTX
Aditxt, Inc.
The Income Pick
ADTX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.71
- Lower volatility, beta 1.71, Low D/E 83.5%, current ratio 0.09x
- Beta 1.71, current ratio 0.09x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TELO | 102.8% revenue growth vs ADTX's -79.2% |
| Quality / Margins | TELO | 1.7% margin vs ADTX's -7.1K% |
| Stability / Safety | ADTX | Beta 1.71 vs TELO's 1.91 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TELO | -46.6% vs ADTX's -100.0% |
| Efficiency (ROA) | ADTX | -156.6% ROA vs TELO's -259.3% |
TELO vs ADTX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLADTXLAGGINGTELO
TELOTelomir Pharmaceutica…
1leads
ADTXAditxt, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs TELOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ADTX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ADTX4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
TELO5/5
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ADTX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ADTX and TELO operate at a comparable scale, with $5,945 and $0 in trailing revenue.
| Metric | TELOTelomir Pharmaceu… | ADTXAditxt, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $5,945 |
| EBITDAEarnings before interest/tax | -$10M | -$20M |
| Net IncomeAfter-tax profit | -$10M | -$42M |
| Free Cash FlowCash after capex | -$4M | -$23M |
| Gross MarginGross profit ÷ Revenue | — | -34.1% |
| Operating MarginEBIT ÷ Revenue | — | -3457.1% |
| Net MarginNet income ÷ Revenue | — | -7105.0% |
| FCF MarginFCF ÷ Revenue | — | -3799.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -89.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.8% | +100.0% |
ADTX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TELO and ADTX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TELOTelomir Pharmaceu… | ADTXAditxt, Inc. |
|---|---|---|
| Market CapShares × price | $46M | $69,911 |
| Enterprise ValueMkt cap + debt − cash | $39M | $6M |
| Trailing P/EPrice ÷ TTM EPS | -4.06x | 0.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.52x |
| Price / BookPrice ÷ Book value/share | 7.17x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TELO and ADTX each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ADTX leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
TELO delivers a -3.2% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-6 for ADTX. On the Piotroski fundamental quality scale (0–9), ADTX scores 4/9 vs TELO's 3/9, reflecting mixed financial health.
| Metric | TELOTelomir Pharmaceu… | ADTXAditxt, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -6.2% |
| ROA (TTM)Return on assets | -2.6% | -156.6% |
| ROICReturn on invested capital | — | -86.1% |
| ROCEReturn on capital employed | -3.2% | -2.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.84x |
| Net DebtTotal debt minus cash | -$7M | $6M |
| Cash & Equiv.Liquid assets | $7M | $833,031 |
| Total DebtShort + long-term debt | $0 | $7M |
| Interest CoverageEBIT ÷ Interest expense | -2574.32x | -19.48x |
ADTX leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
TELO leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TELO five years ago would be worth $1,914 today (with dividends reinvested), compared to $0 for ADTX. Over the past 12 months, TELO leads with a -46.6% total return vs ADTX's -100.0%.
| Metric | TELOTelomir Pharmaceu… | ADTXAditxt, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | 0.0% | -98.1% |
| 1-Year ReturnPast 12 months | -46.6% | -100.0% |
| 3-Year ReturnCumulative with dividends | -80.9% | -100.0% |
| 5-Year ReturnCumulative with dividends | -80.9% | -100.0% |
| 10-Year ReturnCumulative with dividends | -80.9% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -42.4% | — |
TELO leads this category, winning 5 of 5 comparable metrics.
Risk & Volatility
Evenly matched — TELO and ADTX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADTX is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than TELO's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TELO currently trades 43.2% from its 52-week high vs ADTX's 0.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TELOTelomir Pharmaceu… | ADTXAditxt, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.71x |
| 52-Week HighHighest price in past year | $3.10 | $2214.80 |
| 52-Week LowLowest price in past year | $1.05 | $0.12 |
| % of 52W HighCurrent price vs 52-week peak | +43.2% | +0.0% |
| RSI (14)Momentum oscillator 0–100 | 47.3 | 16.4 |
| Avg Volume (50D)Average daily shares traded | 140K | 1.9M |
Evenly matched — TELO and ADTX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TELOTelomir Pharmaceu… | ADTXAditxt, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +100.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ADTX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TELO leads in 1 (Total Returns). 2 tied.
Best OverallAditxt, Inc. (ADTX)Leads 2 of 6 categories
Loading custom metrics...
TELO vs ADTX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — TELO or ADTX?
Over the past 5 years, Telomir Pharmaceuticals, Inc.
Common Stock (TELO) delivered a total return of -80. 9%, compared to -100. 0% for Aditxt, Inc. (ADTX). Over 10 years, the gap is even starker: TELO returned -80. 9% versus ADTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — TELO or ADTX?
By beta (market sensitivity over 5 years), Aditxt, Inc.
(ADTX) is the lower-risk stock at 1. 71β versus Telomir Pharmaceuticals, Inc. Common Stock's 1. 91β — meaning TELO is approximately 12% more volatile than ADTX relative to the S&P 500.
03Which is growing faster — TELO or ADTX?
On earnings-per-share growth, the picture is similar: Telomir Pharmaceuticals, Inc.
Common Stock grew EPS 41. 1% year-over-year, compared to -38. 6% for Aditxt, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — TELO or ADTX?
Telomir Pharmaceuticals, Inc.
Common Stock (TELO) is the more profitable company, earning 0. 0% net margin versus -257. 1% for Aditxt, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TELO leads at 0. 0% versus -208. 0% for ADTX. At the gross margin level — before operating expenses — TELO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TELO or ADTX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TELO or ADTX better for a retirement portfolio?
For long-horizon retirement investors, Aditxt, Inc.
(ADTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Telomir Pharmaceuticals, Inc. Common Stock (TELO) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADTX: -100. 0%, TELO: -80. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TELO and ADTX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.